Observational studyBMC psychiatry2026
Dissociative symptom trajectories during treatment with selective serotonin reuptake inhibitors for depressive or anxiety disorders.
Observational study in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDissociative symptoms often co-occur with depressive and anxiety disorders and may worsen treatment outcomes. Little is known about how different forms of dissociation - psychoform and somatoform - change during pharmacotherapy with selective serotonin reuptake inhibitors (SSRIs).
objectiveOur study examined changes in dissociative symptoms during SSRI treatment of depressive and anxiety disorders and whether they follow a distinct course or are associated with treatment outcomes.
methodWe conducted a longitudinal naturalistic, observational study of 100 outpatients with depressive and/or anxiety symptoms recruited at three outpatient psychiatric clinics, assessed at three time points during SSRI treatment. Measures used included the Hamilton Depression Rating Scale (HDRS), the Hamilton Anxiety Rating Scale (HAM-A), the Dissociative Experiences Scale-Revised (DES-R), and the Somatoform Dissociation Questionnaire-20 (SDQ-20). Changes in symptoms over time were analyzed using nonparametric tests, regression, and cross-lagged correlations.
resultsAll symptoms decreased significantly (p < 0.001), but dissociation declined more slowly than depression and anxiety. Psychoform dissociation declined steadily, whereas somatoform dissociation plateaued after early improvement. Baseline psychoform dissociation was not associated with symptom reduction but significantly reduced the odds of achieving remission of depression. Somatoform dissociation was strongly associated with anxiety, with core anxiety showing a temporal relationship with subsequent severity of dissociative symptoms. Mental anxiety decreased more rapidly than somatic, reflecting slower reduction of somatoform dissociation. Concurrent psychological support was not associated with outcomes.
conclusionsDissociative symptoms may reduce during SSRI treatment, but this reduction is slower and has a different course than that of depressive and anxiety symptoms. Somatoform dissociation is particularly persistent and closely associated with anxiety. Clinicians should screen for dissociation early and consider targeted interventions when appropriate to optimize treatment outcomes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.